Stock REGN REGENERON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Real-time Estimate Cboe BZX
Other stock markets
 09:55:23 2024-04-25 am EDT 		5-day change 1st Jan Change
897.1 USD -1.04% Intraday chart for Regeneron Pharmaceuticals, Inc. +1.26% +3.07%
02:05pm Regeneron Sets Crispr-Based Collaboration With Mammoth Biosciences DJ
01:00pm Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation Crispr-Based Gene Editing for Multiple Diseases CI

Evolution of the average Target Price on Regeneron Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

57a8.A8yGFhtbv96VHntmWCDRMrnpGM03s3UUdXP_wCp3hD0.TovVXiIe0LryRis0IWSea5S7cYtfxzFTMzWMh3kQ52JP_s1ifhXctqFZSw~5b309ed9eb32557487abbf22809f63ac

Analyst Recommendations on Regeneron Pharmaceuticals, Inc.

TD Cowen Adjusts Regeneron Pharmaceuticals' Price Target to $1,030 From $1,020, Keeps Buy Rating MT
UBS Adjusts Regeneron Pharmaceuticals Price Target to $1,099 From $1,090, Maintains Buy Rating MT
ANALYST RECOMMENDATIONS : Las Vegas Sands, Regeneron, Kinder Morgan, Rivian, Royal Caribbean... Our Logo
Goldman Sachs Adjusts Regeneron Pharmaceuticals Price Target to $1,126 From $1,121, Buy Rating Kept MT
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,177 From $1,115, Keeps Overweight Rating MT
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals MT
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals MT
Intellia Therapeutics Ends Co-Development Agreement With Regeneron DJ
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,115 From $1,104, Maintains Overweight Rating MT
RBC Raises Price Target on Regeneron Pharmaceuticals to $1,184 From $1,096, Keeps Outperform Rating MT
RBC Trims Price Target on Regeneron Pharmaceuticals to $1,096 From $1,110, Keeps Outperform Rating MT
Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $925 From $850, Keeps Neutral Rating MT
UBS Adjusts Price Target on Regeneron Pharmaceuticals to $1,090 from $1,112, Maintains Buy Rating MT
Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $880 From $870, Maintains Hold Rating MT
Truist Adjusts Price Target on Regeneron Pharmaceuticals to $1,135 From $1,045, Maintains Buy Rating MT
RBC Lifts Price Target on Regeneron Pharmaceuticals to $1,110 From $1,076 Amid 'Underappreciated' Growth Prospects for Dupixent; Outperform Kept MT
Barclays Adjusts Regeneron Pharmaceuticals' Price Target to $1,050 From $1,020, Keeps Overweight Rating MT
Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,016 From $956, Keeps Overweight Rating MT
Wells Fargo Adjusts Regeneron Pharmaceuticals' Price Target to $1,050 From $980, Keeps Overweight Rating MT
Goldman Sachs Adjusts Regeneron Pharmaceuticals' Price Target to $1,135 From $1,045, Keeps Buy Rating MT
Goldman Sachs Adjusts Regeneron Pharmaceuticals' Price Target to $1,083 From $1,007, Keeps Buy Rating MT
BMO Capital Adjusts Regeneron Pharmaceuticals' Price Target to $1,082 From $1,055, Keeps Outperform Rating MT
Canaccord Genuity Adjusts Regeneron Pharmaceuticals' Price Target to $1,152 From $1,066, Keeps Buy Rating MT
Baird Adjusts Regeneron Pharmaceuticals' Price Target to $940 From $797, Keeps Neutral Rating MT
Job data is good for the economy, not for rate cuts Our Logo
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
906.5 USD
Average target price
1,036 USD
Spread / Average Target
+14.29%
High Price Target
1,189 USD
Spread / Highest target
+31.16%
Low Price Target
720 USD
Spread / Lowest Target
-20.58%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Regeneron Pharmaceuticals, Inc.

TD Cowen
UBS
Goldman Sachs
Morgan Stanley
RBC Capital Markets
Cantor Fitzgerald
Deutsche Bank Securities
Truist Securities
Barclays
Piper Sandler
Wells Fargo Securities
BMO Capital
Canaccord Genuity
Baird
BofA Securities
Jefferies & Co.
Raymond James
WestPark Capital
Oppenheimer
Guggenheim
JPMorgan Chase
SVB Securities LLC
EF Hutton
Cowen
Evercore ISI
Argus
Bernstein
Benchmark Capital
HC Wainwright
SVB Leerink
Credit Suisse

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. REGN Stock
  4. Consensus Regeneron Pharmaceuticals, Inc.